Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease infliximab infection

	Profile	Recent Articles on Subject
1	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission - 8 days ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Imfinzi receives NICE recommendation for lung cancer treatment - 12 days ago Celltrion unveils promising dose escalation results for subcutaneous infliximab - 2 months ago Amgen’s trial brings new hope for IgG4-RD patients - 7 months ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma - 12 days ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 3 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 4 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Ustekinumab-kfce as Biosimilar to Ustekinumab - 19 days ago FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease - about 1 month ago FDA Accepts Biologic License Application for Biosimilar Denosumab - about 2 months ago Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD - 3 months ago FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 3 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 6 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 9 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 10 months ago Results Show Dupilumab Reduces Airway Inflammation In Asthma - 10 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 10 months ago FDA Approves Adalimumab-ryvk as Interchangeable Biosimilar for Humira - 10 months ago Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months - 11 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 11 months ago FDA Approves Targeted Release Budesonide for Treatment of Primary Immunoglobulin A Nephropathy - 12 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - about 1 year ago FDA Grants Breakthrough Therapy Designation to Epcoritamab for Follicular Lymphoma - about 1 year ago FDA Accepts Supplemental Biologics License Application for Hadlima for Interchangeability With Humira - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago Subcutaneous Lecanemab Demonstrates Greater Amyloid Plaque Removal Than Intravenous Lecanemab - about 1 year ago
5	Tara Haelle MedPage Today Sci/health journalist. Feminist. Educator. Photographer. Author. DFW science journalismhealthphotographyteaching	Mirikizumab Effective in Crohn's Disease After Initial Standard Therapy Failure - 22 days ago Risankizumab Beats Ustekinumab for Previously Treated Crohn's - 10 months ago
6	John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. Healthcare journalism	Novel Anti-IgG Drug Hits Mark in Sjogren's Patients - about 1 month ago Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus - 4 months ago Medicare Lags, Medicaid Leads for Biosimilar Uptake - 5 months ago Study Confirms: No Great Options for Treating VEXAS - 7 months ago Novel IL-17A Blocker Continues to Impress in PsA - about 1 year ago Novel Drug OK'd for Ulcerative Colitis - about 1 year ago Bimekizumab Data in axSpA Look Good Through 1 Year - about 1 year ago
7	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - about 1 month ago Dupilumab Reduces Airway Inflammation, Mucus Plugs in Asthma Patients - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 12 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - about 1 year ago New Data on Bimekizumab in Psoriatic Arthritis - about 1 year ago A Novel Mechanism of Action in Treating Relapsing MS - about 1 year ago New Data on CD40 Ligand Inhibitor for Relapsing MS - about 1 year ago
8	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - about 2 months ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - about 2 months ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Lebrikizumab Wins FDA Approval for Eczema - 3 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 10 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - about 1 year ago
10	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - 3 months ago STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation - about 1 year ago

Journalists covering infliximab